JP3122771B2 - 固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法 - Google Patents

固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法

Info

Publication number
JP3122771B2
JP3122771B2 JP09536949A JP53694997A JP3122771B2 JP 3122771 B2 JP3122771 B2 JP 3122771B2 JP 09536949 A JP09536949 A JP 09536949A JP 53694997 A JP53694997 A JP 53694997A JP 3122771 B2 JP3122771 B2 JP 3122771B2
Authority
JP
Japan
Prior art keywords
gene
tissue
cells
cancer
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP09536949A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1997039354A1 (ja
Inventor
治夫 杉山
和司 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPWO1997039354A1 publication Critical patent/JPWO1997039354A1/ja
Application granted granted Critical
Publication of JP3122771B2 publication Critical patent/JP3122771B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP09536949A 1996-04-16 1997-04-15 固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法 Expired - Lifetime JP3122771B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP9405196 1996-04-16
JP8-94051 1996-04-16
JP9405096 1996-04-16
JP8-94050 1996-04-16
JP8-95427 1996-04-17
JP9542796 1996-04-17
PCT/JP1997/001300 WO1997039354A1 (fr) 1996-04-16 1997-04-15 Procede de detection de cellules solides cancereuses et d'heterotypie histologique et procede d'examen du tissu dans le but d'effectuer une transplantation de moelle osseuse et une transplantation de cellules souches du sang peripherique

Publications (2)

Publication Number Publication Date
JPWO1997039354A1 JPWO1997039354A1 (ja) 1998-10-06
JP3122771B2 true JP3122771B2 (ja) 2001-01-09

Family

ID=27307463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09536949A Expired - Lifetime JP3122771B2 (ja) 1996-04-16 1997-04-15 固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法

Country Status (10)

Country Link
US (1) US6225051B1 (fr)
EP (1) EP0846949B1 (fr)
JP (1) JP3122771B2 (fr)
KR (1) KR100262838B1 (fr)
AT (1) ATE298887T1 (fr)
CA (1) CA2224970C (fr)
DE (1) DE69733629T2 (fr)
ES (1) ES2242221T3 (fr)
TW (1) TW562928B (fr)
WO (1) WO1997039354A1 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4789095B2 (ja) * 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US6392257B1 (en) 2000-02-10 2002-05-21 Motorola Inc. Semiconductor structure, semiconductor device, communicating device, integrated circuit, and process for fabricating the same
US6693033B2 (en) 2000-02-10 2004-02-17 Motorola, Inc. Method of removing an amorphous oxide from a monocrystalline surface
CA2404431C (fr) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c servant a deceler les cancers de l'estomac et de l'oesophage
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
KR20030011083A (ko) 2000-05-31 2003-02-06 모토로라 인코포레이티드 반도체 디바이스 및 이를 제조하기 위한 방법
WO2002003437A1 (fr) * 2000-06-30 2002-01-10 Motorola, Inc., A Corporation Of The State Of Delaware Structure et dispositif de semi-conducteur hybride
US6555946B1 (en) 2000-07-24 2003-04-29 Motorola, Inc. Acoustic wave device and process for forming the same
AU2001277001A1 (en) 2000-07-24 2002-02-05 Motorola, Inc. Heterojunction tunneling diodes and process for fabricating same
US6638838B1 (en) 2000-10-02 2003-10-28 Motorola, Inc. Semiconductor structure including a partially annealed layer and method of forming the same
US20020096683A1 (en) 2001-01-19 2002-07-25 Motorola, Inc. Structure and method for fabricating GaN devices utilizing the formation of a compliant substrate
US6673646B2 (en) 2001-02-28 2004-01-06 Motorola, Inc. Growth of compound semiconductor structures on patterned oxide films and process for fabricating same
WO2002082551A1 (fr) 2001-04-02 2002-10-17 Motorola, Inc. Structure de semi-conducteur a courant de fuite attenue
US6709989B2 (en) 2001-06-21 2004-03-23 Motorola, Inc. Method for fabricating a semiconductor structure including a metal oxide interface with silicon
US6992321B2 (en) 2001-07-13 2006-01-31 Motorola, Inc. Structure and method for fabricating semiconductor structures and devices utilizing piezoelectric materials
US6531740B2 (en) 2001-07-17 2003-03-11 Motorola, Inc. Integrated impedance matching and stability network
US6646293B2 (en) 2001-07-18 2003-11-11 Motorola, Inc. Structure for fabricating high electron mobility transistors utilizing the formation of complaint substrates
US6693298B2 (en) 2001-07-20 2004-02-17 Motorola, Inc. Structure and method for fabricating epitaxial semiconductor on insulator (SOI) structures and devices utilizing the formation of a compliant substrate for materials used to form same
US7019332B2 (en) 2001-07-20 2006-03-28 Freescale Semiconductor, Inc. Fabrication of a wavelength locker within a semiconductor structure
US6855992B2 (en) 2001-07-24 2005-02-15 Motorola Inc. Structure and method for fabricating configurable transistor devices utilizing the formation of a compliant substrate for materials used to form the same
US6667196B2 (en) 2001-07-25 2003-12-23 Motorola, Inc. Method for real-time monitoring and controlling perovskite oxide film growth and semiconductor structure formed using the method
US6639249B2 (en) 2001-08-06 2003-10-28 Motorola, Inc. Structure and method for fabrication for a solid-state lighting device
US6589856B2 (en) 2001-08-06 2003-07-08 Motorola, Inc. Method and apparatus for controlling anti-phase domains in semiconductor structures and devices
US20030034491A1 (en) 2001-08-14 2003-02-20 Motorola, Inc. Structure and method for fabricating semiconductor structures and devices for detecting an object
US6673667B2 (en) 2001-08-15 2004-01-06 Motorola, Inc. Method for manufacturing a substantially integral monolithic apparatus including a plurality of semiconductor materials
WO2003020899A2 (fr) * 2001-08-31 2003-03-13 Diadexus, Inc. Compositions et methodes relatives a des genes et proteines specifiques des poumons
US20030071327A1 (en) 2001-10-17 2003-04-17 Motorola, Inc. Method and apparatus utilizing monocrystalline insulator
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
US6916717B2 (en) 2002-05-03 2005-07-12 Motorola, Inc. Method for growing a monocrystalline oxide layer and for fabricating a semiconductor device on a monocrystalline substrate
US7169619B2 (en) 2002-11-19 2007-01-30 Freescale Semiconductor, Inc. Method for fabricating semiconductor structures on vicinal substrates using a low temperature, low pressure, alkaline earth metal-rich process
US6885065B2 (en) 2002-11-20 2005-04-26 Freescale Semiconductor, Inc. Ferromagnetic semiconductor structure and method for forming the same
US6965128B2 (en) 2003-02-03 2005-11-15 Freescale Semiconductor, Inc. Structure and method for fabricating semiconductor microresonator devices
US7020374B2 (en) 2003-02-03 2006-03-28 Freescale Semiconductor, Inc. Optical waveguide structure and method for fabricating the same
WO2005001117A1 (fr) * 2003-06-27 2005-01-06 Haruo Sugiyama Procede de selection d'un patient s'adaptant au vaccin anti-wt1
WO2005092393A1 (fr) * 2004-03-29 2005-10-06 Haruo Sugiyama Micro arn inhibant l'expression du gene wt1 et utilisation de celui-ci
EP1738771A4 (fr) * 2004-03-29 2010-04-21 Haruo Sugiyama ARNsi CAPABLE D'INHIBER L'EXPRESSION DU GENE WT1 ET UTILISATION DE CELUI-CI
EP1657250A1 (fr) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin Lymphocyte T épitope de WT1 qui se lie à HLA-A *01
EP2402758B1 (fr) 2005-09-19 2014-09-10 Janssen Diagnostics, LLC Procédés et utilisations pour identifier l'origine d'un carcinome d'origine primaire inconnue
WO2008058018A2 (fr) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Prédiction de l'évolution d'un cancer
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (fr) 2009-05-07 2018-09-26 Veracyte, Inc. Procédés pour le diagnostic d'affections thyroïdiennes
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
CA2839663A1 (fr) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Gene recepteur pour un lymphocyte t specifique d'un antigene cancereux peptidique
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2885640B1 (fr) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prognostic du cancer de la prostate au moyen de biomarqueurs
EP2968988A4 (fr) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (fr) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
WO2018132916A1 (fr) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Sous-typage moléculaire, pronostic et traitement du cancer de la vessie
CA3055925A1 (fr) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour predire la reponse a une therapie hormonale
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (fr) 2017-08-04 2019-02-07 Genomedx, Inc. Utilisation d'une expression génique spécifique des cellules immunitaires pour le pronostic du cancer de la prostate et la prédiction de la sensibilité à la radiothérapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＡＭＥＲＩＣＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＡＴＨＯＬＯＧＹ，ＶＯＬ．１４０，ＮＯ．５（１９９２），ｐ．１０３１−１０３７
ＣＡＮＣＥＲ ＩＮＶＥＳＴＩＧＡＴＩＯＮ，ＶＯＬ．１１，ＮＯ．４，（１９９３），ｐ．３９３−３９９

Also Published As

Publication number Publication date
EP0846949B1 (fr) 2005-06-29
DE69733629T2 (de) 2006-05-18
TW562928B (en) 2003-11-21
EP0846949A4 (fr) 2002-11-13
DE69733629D1 (de) 2005-08-04
WO1997039354A1 (fr) 1997-10-23
ES2242221T3 (es) 2005-11-01
KR19990022939A (ko) 1999-03-25
CA2224970A1 (fr) 1997-10-23
EP0846949A1 (fr) 1998-06-10
ATE298887T1 (de) 2005-07-15
US6225051B1 (en) 2001-05-01
CA2224970C (fr) 2002-04-02
KR100262838B1 (ko) 2003-03-15

Similar Documents

Publication Publication Date Title
JP3122771B2 (ja) 固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法
JPWO1997039354A1 (ja) 固形癌細胞及び組織異型性の検出方法並びに骨髄移植及び末梢血幹細胞移植用組織の検査方法
Mattano Jr et al. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction
Schaich et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
Bostick et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.
Vaughan et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
US7098008B2 (en) Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
Wallace et al. Detection of the bcl-2 t (14; 18) translocation and proto-oncogene expression in primary intraocular lymphoma
Solmi et al. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR.
CA2451483C (fr) Methodes de detection et de surveillance du taux d'arn de cox-2 dans le plasma et le serum
CN103540589A (zh) Tert启动子的单核苷酸多态性序列
US20100330554A1 (en) Diagnostic kit for solid cancer and medicament for solid cancer therapy
EP1959022B1 (fr) Detection d un leiomyosarcome uterin au moyen de lmp2
JPH08500731A (ja) 診断法
WO2001053535A2 (fr) Procede de detection de croissance ou de proliferation cellulaire neoplasique, hyperplasique, cytologiquement dysplasique et/ou premaligne
EP1354060A2 (fr) Detection d'arn 5t4 dans le plasma et le serum
KR102856145B1 (ko) 말초 t세포 림프종 예후 예측용 신규 바이오마커 및 이의 용도
Torà et al. Detection of HuD transcripts by means of reverse transcriptase and polymerase chain reaction: implications for the detection of minimal residual disease in patients with small cell lung cancer
US8354243B2 (en) Method for determining presence of cancer in a sample by assaying for expression of ECSA/DPPA-2 nucleotide sequences
US7355025B2 (en) Marker molecules associated with lung tumors
JP4923252B2 (ja) 癌の判定方法および癌診断キット
EP2189527B1 (fr) Procédé de diagnostic du cancer
US20090311671A1 (en) Diagnosis of risk of breast cancer
KR101528331B1 (ko) 조직 및 혈액을 이용한 유방암의 치료제 선별 검사 및 조기진단을 위한 역전사 정량적 중합효소연쇄반응 키트
Luzzatto Applications of Molecular Biology in Modern Medicine

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111027

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121027

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131027

Year of fee payment: 13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term